<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>VERVE-101/102 - In Vivo Base Editing for PCSK9</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        :root {
            --primary: #0066CC;
            --primary-light: #E8F2FF;
            --success: #00A86B;
            --warning: #F39C12;
            --danger: #E74C3C;
            --text-primary: #2C3E50;
            --text-secondary: #7F8C8D;
            --border: #E1E8ED;
            --background: #FFFFFF;
            --background-alt: #F8FAFB;
            --shadow-sm: 0 1px 3px rgba(0,0,0,0.08);
            --shadow-md: 0 4px 6px rgba(0,0,0,0.1);
            --shadow-lg: 0 10px 25px rgba(0,0,0,0.1);
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Inter', Roboto, sans-serif;
            background: var(--background-alt);
            color: var(--text-primary);
            line-height: 1.6;
            font-size: 14px;
        }
        
        /* Header */
        .header {
            background: white;
            border-bottom: 1px solid var(--border);
            padding: 16px 24px;
            position: sticky;
            top: 0;
            z-index: 100;
            box-shadow: var(--shadow-sm);
        }
        
        .header-content {
            max-width: 1400px;
            margin: 0 auto;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }
        
        .back-button {
            display: inline-flex;
            align-items: center;
            gap: 8px;
            padding: 8px 16px;
            background: var(--background-alt);
            border: 1px solid var(--border);
            border-radius: 6px;
            color: var(--text-primary);
            text-decoration: none;
            font-size: 14px;
            transition: all 0.2s;
        }
        
        .back-button:hover {
            background: var(--primary-light);
            border-color: var(--primary);
            color: var(--primary);
        }
        
        .header-badges {
            display: flex;
            gap: 8px;
        }
        
        .status-badge {
            padding: 8px 16px;
            background: #FDEDEC;
            color: var(--danger);
            border: 1px solid var(--danger);
            border-radius: 20px;
            font-weight: 600;
            font-size: 12px;
        }
        
        .acquisition-badge {
            padding: 8px 16px;
            background: #E6F7ED;
            color: var(--success);
            border: 1px solid var(--success);
            border-radius: 20px;
            font-weight: 600;
            font-size: 12px;
        }
        
        /* Container */
        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: 24px;
        }
        
        /* Hero Section */
        .hero-section {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 32px;
            margin-bottom: 24px;
            box-shadow: var(--shadow-sm);
        }
        
        .drug-title {
            margin-bottom: 24px;
        }
        
        .drug-name {
            font-size: 32px;
            font-weight: 700;
            color: var(--text-primary);
            margin-bottom: 8px;
        }
        
        .drug-company {
            font-size: 16px;
            color: var(--text-secondary);
            margin-bottom: 12px;
        }
        
        .drug-mechanism {
            display: inline-block;
            padding: 6px 16px;
            background: var(--primary-light);
            color: var(--primary);
            border-radius: 20px;
            font-size: 14px;
            font-weight: 500;
        }
        
        /* Stats Grid */
        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 16px;
            margin-bottom: 24px;
        }
        
        .stat-card {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 16px;
            box-shadow: var(--shadow-sm);
        }
        
        .stat-value {
            font-size: 24px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 4px;
        }
        
        .stat-label {
            font-size: 12px;
            color: var(--text-secondary);
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        /* Navigation Tabs */
        .nav-tabs {
            display: flex;
            gap: 8px;
            margin-bottom: 24px;
            background: white;
            padding: 8px;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }
        
        .nav-tab {
            padding: 10px 20px;
            background: transparent;
            border: none;
            border-radius: 6px;
            color: var(--text-secondary);
            cursor: pointer;
            transition: all 0.2s;
            font-size: 14px;
            font-weight: 500;
            white-space: nowrap;
        }
        
        .nav-tab:hover {
            background: var(--background-alt);
            color: var(--text-primary);
        }
        
        .nav-tab.active {
            background: var(--primary-light);
            color: var(--primary);
        }
        
        /* Tab Content */
        .tab-content {
            display: none;
        }
        
        .tab-content.active {
            display: block;
        }
        
        /* Section Styles */
        .section {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 24px;
            margin-bottom: 24px;
            box-shadow: var(--shadow-sm);
        }
        
        .section-header {
            font-size: 18px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 20px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }
        
        /* Alert Boxes */
        .alert {
            padding: 16px;
            border-radius: 6px;
            margin: 16px 0;
            display: flex;
            align-items: flex-start;
            gap: 12px;
        }
        
        .alert-danger {
            background: #FDEDEC;
            border: 1px solid var(--danger);
            color: #721C24;
        }
        
        .alert-warning {
            background: #FFF4E6;
            border: 1px solid var(--warning);
            color: #856404;
        }
        
        .alert-info {
            background: var(--primary-light);
            border: 1px solid var(--primary);
            color: var(--primary);
        }
        
        .alert-success {
            background: #E6F7ED;
            border: 1px solid var(--success);
            color: #155724;
        }
        
        .alert-icon {
            font-size: 16px;
            flex-shrink: 0;
        }
        
        .alert-content {
            flex: 1;
            font-size: 13px;
            line-height: 1.5;
        }
        
        /* Info Cards */
        .info-card {
            background: var(--background-alt);
            border-left: 4px solid var(--primary);
            padding: 16px;
            border-radius: 4px;
            margin-bottom: 16px;
        }
        
        .info-card h3 {
            font-size: 14px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 8px;
        }
        
        .info-card p,
        .info-card ul {
            font-size: 13px;
            color: var(--text-secondary);
            line-height: 1.6;
        }
        
        .info-card ul {
            margin-left: 20px;
            margin-top: 8px;
        }
        
        /* Process Steps */
        .process-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(150px, 1fr));
            gap: 16px;
            margin: 20px 0;
        }
        
        .process-step {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 16px;
            text-align: center;
            position: relative;
            transition: all 0.2s;
        }
        
        .process-step:hover {
            box-shadow: var(--shadow-md);
            transform: translateY(-2px);
        }
        
        .step-number {
            position: absolute;
            top: -10px;
            left: 50%;
            transform: translateX(-50%);
            background: var(--primary);
            color: white;
            width: 24px;
            height: 24px;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 12px;
            font-weight: bold;
        }
        
        .step-title {
            font-size: 13px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 4px;
            margin-top: 8px;
        }
        
        .step-description {
            font-size: 11px;
            color: var(--text-secondary);
        }
        
        /* Timeline */
        .timeline {
            position: relative;
            padding: 20px 0;
        }
        
        .timeline-line {
            position: absolute;
            left: 12px;
            top: 0;
            bottom: 0;
            width: 2px;
            background: var(--border);
        }
        
        .timeline-item {
            position: relative;
            padding-left: 40px;
            margin-bottom: 24px;
        }
        
        .timeline-dot {
            position: absolute;
            left: 4px;
            top: 4px;
            width: 18px;
            height: 18px;
            background: white;
            border: 3px solid var(--primary);
            border-radius: 50%;
        }
        
        .timeline-item.complete .timeline-dot {
            background: var(--primary);
        }
        
        .timeline-item.paused .timeline-dot {
            background: var(--danger);
            border-color: var(--danger);
        }
        
        .timeline-item.future .timeline-dot {
            border-style: dashed;
            background: var(--background-alt);
        }
        
        .timeline-content {
            background: var(--background-alt);
            padding: 12px 16px;
            border-radius: 6px;
            border: 1px solid var(--border);
        }
        
        .timeline-date {
            font-size: 12px;
            font-weight: 600;
            color: var(--primary);
            margin-bottom: 4px;
        }
        
        .timeline-title {
            font-size: 14px;
            color: var(--text-primary);
            font-weight: 500;
            margin-bottom: 4px;
        }
        
        .timeline-description {
            font-size: 12px;
            color: var(--text-secondary);
            margin-top: 4px;
        }
        
        /* Data Tables */
        .data-table {
            width: 100%;
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            overflow: hidden;
            box-shadow: var(--shadow-sm);
        }
        
        .data-table thead {
            background: var(--background-alt);
        }
        
        .data-table th {
            padding: 12px 16px;
            text-align: left;
            font-size: 12px;
            font-weight: 600;
            color: var(--text-secondary);
            text-transform: uppercase;
            letter-spacing: 0.5px;
            border-bottom: 2px solid var(--border);
        }
        
        .data-table td {
            padding: 12px 16px;
            font-size: 13px;
            color: var(--text-primary);
            border-bottom: 1px solid var(--border);
        }
        
        .data-table tbody tr:hover {
            background: var(--background-alt);
        }
        
        .data-table tbody tr:last-child td {
            border-bottom: none;
        }
        
        /* Comparison Table */
        .comparison-card {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 20px;
            margin-bottom: 16px;
        }
        
        .comparison-header {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 1px solid var(--border);
        }
        
        .comparison-title {
            font-size: 16px;
            font-weight: 600;
            color: var(--text-primary);
        }
        
        /* Efficacy Chart */
        .efficacy-chart {
            background: var(--background-alt);
            padding: 20px;
            border-radius: 8px;
            margin-top: 16px;
        }
        
        .chart-container {
            display: flex;
            align-items: flex-end;
            justify-content: space-around;
            height: 200px;
            margin-top: 20px;
        }
        
        .chart-bar-wrapper {
            display: flex;
            flex-direction: column;
            align-items: center;
            flex: 1;
        }
        
        .chart-value {
            font-size: 14px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 8px;
        }
        
        .chart-bar {
            width: 60px;
            background: var(--primary);
            border-radius: 4px 4px 0 0;
            transition: all 0.3s;
        }
        
        .chart-bar.secondary {
            background: var(--text-secondary);
        }
        
        .chart-bar.success {
            background: var(--success);
        }
        
        .chart-bar.warning {
            background: var(--warning);
        }
        
        .chart-label {
            font-size: 11px;
            color: var(--text-secondary);
            text-align: center;
            margin-top: 8px;
        }
        
        /* Safety Grid */
        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 12px;
            margin-top: 16px;
        }
        
        .safety-item {
            background: white;
            border: 1px solid var(--border);
            border-radius: 6px;
            padding: 12px;
            text-align: center;
        }
        
        .safety-item.resolved {
            border-left: 3px solid var(--success);
        }
        
        .safety-item.concern {
            border-left: 3px solid var(--danger);
        }
        
        .safety-item.monitoring {
            border-left: 3px solid var(--warning);
        }
        
        .safety-value {
            font-size: 18px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 4px;
        }
        
        .safety-label {
            font-size: 11px;
            color: var(--text-secondary);
        }
        
        /* Badge */
        .badge {
            display: inline-block;
            padding: 2px 8px;
            border-radius: 12px;
            font-size: 11px;
            font-weight: 600;
            margin-left: 8px;
        }
        
        .badge-danger {
            background: #FDEDEC;
            color: var(--danger);
        }
        
        .badge-warning {
            background: #FFF4E6;
            color: var(--warning);
        }
        
        .badge-success {
            background: #E6F7ED;
            color: var(--success);
        }
        
        .badge-info {
            background: var(--primary-light);
            color: var(--primary);
        }
        
        /* Pipeline Visual */
        .pipeline-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 16px;
            margin: 20px 0;
        }
        
        .pipeline-item {
            background: white;
            border: 2px solid var(--border);
            border-radius: 8px;
            padding: 16px;
            text-align: center;
            transition: all 0.2s;
        }
        
        .pipeline-item.active {
            border-color: var(--primary);
            background: var(--primary-light);
        }
        
        .pipeline-item:hover {
            box-shadow: var(--shadow-md);
            transform: translateY(-2px);
        }
        
        .pipeline-name {
            font-size: 14px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 4px;
        }
        
        .pipeline-target {
            font-size: 12px;
            color: var(--text-secondary);
            margin-bottom: 8px;
        }
        
        .pipeline-status {
            font-size: 11px;
            color: var(--primary);
            font-weight: 500;
        }
        
        /* Responsive */
        @media (max-width: 768px) {
            .container {
                padding: 16px;
            }
            
            .drug-name {
                font-size: 24px;
            }
            
            .stats-grid {
                grid-template-columns: 1fr 1fr;
            }
            
            .process-grid {
                grid-template-columns: 1fr 1fr;
            }
            
            .nav-tabs {
                overflow-x: auto;
            }
            
            .pipeline-grid {
                grid-template-columns: 1fr;
            }
        }
        
        /* Links */
        a {
            color: var(--primary);
            text-decoration: none;
        }
        
        a:hover {
            text-decoration: underline;
        }
        
        .source-link {
            font-size: 11px;
            color: var(--primary);
            margin-left: 4px;
        }
    </style>
</head>
<body>
    <header class="header">
        <div class="header-content">
            <a href="index.html" class="back-button">
                ← Back to Dashboard
            </a>
            <div class="header-badges">
                <div class="status-badge">PHASE 1 - PAUSED/PIVOTED</div>
                <div class="acquisition-badge">LILLY ACQUISITION $1B</div>
            </div>
        </div>
    </header>

    <div class="container">
        <!-- Hero Section -->
        <div class="hero-section">
            <div class="drug-title">
                <h1 class="drug-name">VERVE-101 / VERVE-102</h1>
                <div class="drug-company">Verve Therapeutics → Eli Lilly (Acquired July 25, 2025)</div>
                <div class="drug-mechanism">First-in-Class In Vivo Base Editing Therapy</div>
            </div>
            
            <div class="stats-grid">
                <div class="stat-card">
                    <div class="stat-value">One-Time</div>
                    <div class="stat-label">Treatment Paradigm</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">50-70%</div>
                    <div class="stat-label">LDL Reduction (Permanent)</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">2028-2030</div>
                    <div class="stat-label">Potential Approval</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">$1-2M</div>
                    <div class="stat-label">Expected Price Range</div>
                </div>
            </div>
        </div>

        <!-- Navigation Tabs -->
        <div class="nav-tabs">
            <button class="nav-tab active" onclick="showTab('overview')">Overview</button>
            <button class="nav-tab" onclick="showTab('technology')">Technology</button>
            <button class="nav-tab" onclick="showTab('regulatory')">Regulatory</button>
            <button class="nav-tab" onclick="showTab('clinical')">Clinical Trials</button>
            <button class="nav-tab" onclick="showTab('safety')">Safety</button>
            <button class="nav-tab" onclick="showTab('commercial')">Commercial</button>
            <button class="nav-tab" onclick="showTab('future')">Future Outlook</button>
        </div>

        <!-- Overview Tab -->
        <div id="overview" class="tab-content active">
            <div class="alert alert-danger">
                <span class="alert-icon">🎯</span>
                <div class="alert-content">
                    <strong>Paradigm Shift Alert:</strong> One-time IV infusion permanently inactivates PCSK9 gene in liver cells, potentially providing lifelong LDL-C reduction. This is not a drug - it's a functional cure for high cholesterol through precise DNA editing. <a href="https://fiercebiotech.com" class="source-link">[Source]</a>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Key Information</h2>
                
                <div class="info-card">
                    <h3>What is VERVE-101/102?</h3>
                    <p>An investigational gene-editing therapy using CRISPR-derived base-editing technology to permanently reduce cholesterol. It makes a single-letter change in the DNA of liver cells to turn off PCSK9 production forever.</p>
                    <ul>
                        <li>Uses adenine base editor (ABE) - no double-strand DNA breaks</li>
                        <li>Delivered via lipid nanoparticle (LNP) to liver</li>
                        <li>Single IV infusion intended to last a lifetime</li>
                        <li>Mimics natural PCSK9 mutations that protect against heart disease</li>
                    </ul>
                </div>

                <div class="info-card">
                    <h3>Current Status</h3>
                    <ul>
                        <li><strong>VERVE-101:</strong> Paused April 2024 due to safety concerns (liver enzyme elevation, low platelets)</li>
                        <li><strong>VERVE-102:</strong> Improved version with better LNP formulation, IND cleared March 2025</li>
                        <li><strong>Heart-2 Trial:</strong> Starting H2 2025 with VERVE-102</li>
                        <li><strong>Lilly Acquisition:</strong> Completed July 25, 2025 for ~$1 billion <a href="https://fiercebiotech.com" class="source-link">[Source]</a></li>
                    </ul>
                </div>

                <h3 style="margin-top: 24px; margin-bottom: 16px; font-size: 16px;">Pipeline Programs</h3>
                <div class="pipeline-grid">
                    <div class="pipeline-item active">
                        <div class="pipeline-name">VERVE-102</div>
                        <div class="pipeline-target">PCSK9 (HeFH/ASCVD)</div>
                        <div class="pipeline-status">Phase 1b/2 Starting</div>
                    </div>
                    <div class="pipeline-item">
                        <div class="pipeline-name">VERVE-201</div>
                        <div class="pipeline-target">ANGPTL3 (HoFH)</div>
                        <div class="pipeline-status">IND-Enabling</div>
                    </div>
                    <div class="pipeline-item">
                        <div class="pipeline-name">VERVE-301</div>
                        <div class="pipeline-target">Lp(a) Reduction</div>
                        <div class="pipeline-status">Research Stage</div>
                    </div>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Competitive Positioning</h2>
                
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Approach</th>
                            <th>Frequency</th>
                            <th>LDL Reduction</th>
                            <th>Reversibility</th>
                            <th>Market Timeline</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr style="background: var(--primary-light);">
                            <td><strong>VERVE Gene Editing</strong></td>
                            <td>Once lifetime</td>
                            <td>50-70%</td>
                            <td>Irreversible</td>
                            <td>2028-2030</td>
                        </tr>
                        <tr>
                            <td>Inclisiran (siRNA)</td>
                            <td>2x/year</td>
                            <td>50%</td>
                            <td>Reversible</td>
                            <td>Approved</td>
                        </tr>
                        <tr>
                            <td>PCSK9 mAbs</td>
                            <td>Monthly</td>
                            <td>60%</td>
                            <td>Reversible</td>
                            <td>Approved</td>
                        </tr>
                        <tr>
                            <td>Oral PCSK9i</td>
                            <td>Daily</td>
                            <td>60%</td>
                            <td>Reversible</td>
                            <td>2026-2027</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- Technology Tab -->
        <div id="technology" class="tab-content">
            <div class="section">
                <h2 class="section-header">How Base Editing Works</h2>
                
                <div class="process-grid">
                    <div class="process-step">
                        <div class="step-number">1</div>
                        <div class="step-title">Delivery</div>
                        <div class="step-description">LNP carries mRNA for base editor + guide RNA to liver via IV</div>
                    </div>
                    <div class="process-step">
                        <div class="step-number">2</div>
                        <div class="step-title">Targeting</div>
                        <div class="step-description">Guide RNA directs editor to PCSK9 gene in hepatocytes</div>
                    </div>
                    <div class="process-step">
                        <div class="step-number">3</div>
                        <div class="step-title">Editing</div>
                        <div class="step-description">ABE makes precise A→G change without cutting DNA</div>
                    </div>
                    <div class="process-step">
                        <div class="step-number">4</div>
                        <div class="step-title">Result</div>
                        <div class="step-description">Introduces stop codon, halting PCSK9 production</div>
                    </div>
                    <div class="process-step">
                        <div class="step-number">5</div>
                        <div class="step-title">Effect</div>
                        <div class="step-description">50-70% of liver cells edited, 80-90% PCSK9↓</div>
                    </div>
                    <div class="process-step">
                        <div class="step-number">6</div>
                        <div class="step-title">Outcome</div>
                        <div class="step-description">50-70% LDL reduction sustained indefinitely</div>
                    </div>
                </div>

                <div class="info-card">
                    <h3>Technical Specifications</h3>
                    <ul>
                        <li><strong>Editor Type:</strong> Adenine Base Editor (ABE) - Cas9 nickase + TadA deaminase</li>
                        <li><strong>Target:</strong> PCSK9 gene exon 1 - introduces premature stop codon</li>
                        <li><strong>Delivery:</strong> Liver-targeted LNP (similar to COVID vaccines but optimized)</li>
                        <li><strong>Editing Efficiency:</strong> 50-70% of hepatocytes at therapeutic doses</li>
                        <li><strong>Off-target Rate:</strong> <0.1% genome-wide (WGS validated)</li>
                        <li><strong>Germline Risk:</strong> Minimal - no gonadal LNP distribution shown <a href="https://fiercebiotech.com" class="source-link">[Source]</a></li>
                    </ul>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">VERVE-101 vs VERVE-102</h2>
                
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Feature</th>
                            <th>VERVE-101</th>
                            <th>VERVE-102 (Improved)</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>LNP Formulation</strong></td>
                            <td>First-generation LNP</td>
                            <td>GalNAc-conjugated (enhanced liver targeting)</td>
                        </tr>
                        <tr>
                            <td><strong>Status</strong></td>
                            <td><span class="badge badge-danger">Paused April 2024</span></td>
                            <td><span class="badge badge-success">IND Cleared March 2025</span></td>
                        </tr>
                        <tr>
                            <td><strong>Tolerability</strong></td>
                            <td>Grade 3 ALT elevations, thrombocytopenia</td>
                            <td>Expected improved safety profile</td>
                        </tr>
                        <tr>
                            <td><strong>Dosing</strong></td>
                            <td>0.1-0.6 mg/kg tested</td>
                            <td>Potentially lower doses needed</td>
                        </tr>
                        <tr>
                            <td><strong>Trial</strong></td>
                            <td>Heart-1 (paused)</td>
                            <td>Heart-2 (starting H2 2025)</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- Regulatory Tab -->
        <div id="regulatory" class="tab-content">
            <div class="section">
                <h2 class="section-header">FDA Regulatory Timeline</h2>
                
                <div class="alert alert-warning">
                    <span class="alert-icon">⚠️</span>
                    <div class="alert-content">
                        As the first in vivo base editing therapy, VERVE faces unprecedented regulatory scrutiny. Every step sets precedent for the entire field.
                    </div>
                </div>
                
                <div class="timeline">
                    <div class="timeline-line"></div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">October 2022</div>
                            <div class="timeline-title">IND Submission</div>
                            <div class="timeline-description">First IND for in vivo base editing submitted to FDA</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item paused">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">November 2022</div>
                            <div class="timeline-title">FDA Clinical Hold</div>
                            <div class="timeline-description">Concerns: germline editing, off-targets, potency, LNP safety <a href="https://fiercebiotech.com" class="source-link">[Source]</a></div>
                        </div>
                    </div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">2022-2023</div>
                            <div class="timeline-title">Ex-US Trial Start</div>
                            <div class="timeline-description">Trials began in New Zealand and UK while FDA hold active</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">October 2023</div>
                            <div class="timeline-title">FDA Hold Lifted</div>
                            <div class="timeline-description">Comprehensive safety data satisfied FDA concerns <a href="https://fiercebiotech.com" class="source-link">[Source]</a></div>
                        </div>
                    </div>
                    
                    <div class="timeline-item paused">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">April 2024</div>
                            <div class="timeline-title">Voluntary Pause</div>
                            <div class="timeline-description">Heart-1 paused due to Grade 3 ALT elevation and thrombocytopenia</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">March 2025</div>
                            <div class="timeline-title">VERVE-102 IND Cleared</div>
                            <div class="timeline-description">FDA approves improved version with better LNP</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">July 25, 2025</div>
                            <div class="timeline-title">Lilly Acquisition</div>
                            <div class="timeline-description">$1B deal complete, enhanced resources <a href="https://biopharmadive.com" class="source-link">[Source]</a></div>
                        </div>
                    </div>
                    
                    <div class="timeline-item future">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">H2 2025</div>
                            <div class="timeline-title">Heart-2 Start</div>
                            <div class="timeline-description">Phase 1b/2 trial initiation expected</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item future">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">2028-2030</div>
                            <div class="timeline-title">Potential BLA</div>
                            <div class="timeline-description">If Phase 3 successful, multi-year follow-up required</div>
                        </div>
                    </div>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Global Regulatory Status</h2>
                
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Region</th>
                            <th>Status</th>
                            <th>Key Events</th>
                            <th>Timeline</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>FDA (US)</strong></td>
                            <td><span class="badge badge-info">Phase 1</span></td>
                            <td>Hold lifted, VERVE-102 IND cleared</td>
                            <td>BLA ~2028-2030</td>
                        </tr>
                        <tr>
                            <td><strong>EMA (EU)</strong></td>
                            <td><span class="badge badge-warning">Pre-clinical</span></td>
                            <td>No hold, more permissive initially</td>
                            <td>MAA ~2030</td>
                        </tr>
                        <tr>
                            <td><strong>MHRA (UK)</strong></td>
                            <td><span class="badge badge-info">Phase 1</span></td>
                            <td>First to approve human trials</td>
                            <td>Active sites</td>
                        </tr>
                        <tr>
                            <td><strong>Medsafe (NZ)</strong></td>
                            <td><span class="badge badge-info">Phase 1</span></td>
                            <td>Enabled first-in-human dosing</td>
                            <td>Active sites</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- Clinical Trials Tab -->
        <div id="clinical" class="tab-content">
            <div class="section">
                <h2 class="section-header">Clinical Development Program</h2>
                
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Trial</th>
                            <th>Phase</th>
                            <th>N</th>
                            <th>Population</th>
                            <th>Status</th>
                            <th>Key Results</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Preclinical</strong></td>
                            <td>Pre</td>
                            <td>~50</td>
                            <td>Non-human primates</td>
                            <td>Complete</td>
                            <td>89% PCSK9↓, 69% LDL↓ >2.5yr <a href="https://fiercebiotech.com" class="source-link">[Source]</a></td>
                        </tr>
                        <tr>
                            <td><strong>Heart-1</strong><br>(NCT05398029)</td>
                            <td>1b</td>
                            <td>44 planned<br>~12 dosed</td>
                            <td>HeFH/ASCVD</td>
                            <td><span class="badge badge-danger">Paused</span></td>
                            <td>83% PCSK9↓, 55% LDL↓<br>Safety issues at 0.6 mg/kg</td>
                        </tr>
                        <tr>
                            <td><strong>Heart-2</strong><br>(VERVE-102)</td>
                            <td>1b/2</td>
                            <td>~100</td>
                            <td>HeFH/CAD</td>
                            <td><span class="badge badge-info">Starting H2 2025</span></td>
                            <td>—</td>
                        </tr>
                        <tr>
                            <td><strong>Long-term Registry</strong></td>
                            <td>4</td>
                            <td>All pts</td>
                            <td>All treated</td>
                            <td>Ongoing</td>
                            <td>5-15 year follow-up planned</td>
                        </tr>
                    </tbody>
                </table>

                <div class="alert alert-info">
                    <span class="alert-icon">📊</span>
                    <div class="alert-content">
                        <strong>No CV Outcomes Trials Yet:</strong> Approval will rely on LDL-C as surrogate endpoint with post-marketing outcomes commitment. Expected 50-80% lifetime MACE reduction if given early, based on genetic data.
                    </div>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Efficacy Results</h2>
                
                <div class="efficacy-chart">
                    <h3 style="font-size: 14px; margin-bottom: 16px;">Heart-1 Interim Data (High Dose Cohort)</h3>
                    <div class="chart-container">
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">83%</div>
                            <div class="chart-bar" style="height: 83%;"></div>
                            <div class="chart-label">PCSK9<br>Reduction</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">55%</div>
                            <div class="chart-bar" style="height: 55%;"></div>
                            <div class="chart-label">LDL-C<br>Reduction<br>(Day 180)</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">46%</div>
                            <div class="chart-bar" style="height: 46%;"></div>
                            <div class="chart-label">LDL-C<br>Reduction<br>(Low dose)</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">45%</div>
                            <div class="chart-bar secondary" style="height: 45%;"></div>
                            <div class="chart-label">ApoB<br>Reduction</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">30%</div>
                            <div class="chart-bar warning" style="height: 30%;"></div>
                            <div class="chart-label">Lp(a)<br>Reduction</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">88%</div>
                            <div class="chart-bar success" style="height: 88%;"></div>
                            <div class="chart-label">Projected<br>CAD Risk↓</div>
                        </div>
                    </div>
                </div>

                <div class="info-card" style="margin-top: 20px;">
                    <h3>Durability Profile</h3>
                    <ul>
                        <li><strong>Primate Data:</strong> >2.5 years sustained effect with no rebound</li>
                        <li><strong>Human Projection:</strong> Expected lifelong effect from single infusion</li>
                        <li><strong>Editing Coverage:</strong> 50-70% hepatocytes edited at therapeutic doses</li>
                        <li><strong>Genetic Comparison:</strong> Mimics PCSK9 R46L carriers (88% lower CAD risk)</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Safety Tab -->
        <div id="safety" class="tab-content">
            <div class="section">
                <h2 class="section-header">Safety Profile</h2>
                
                <div class="alert alert-danger">
                    <span class="alert-icon">⚠️</span>
                    <div class="alert-content">
                        <strong>Critical Safety Event:</strong> Heart-1 paused April 2024 due to Grade 3 ALT elevation and thrombocytopenia at 0.6 mg/kg dose. Led to complete redesign with VERVE-102.
                    </div>
                </div>
                
                <div class="safety-grid">
                    <div class="safety-item concern">
                        <div class="safety-value">Grade 3</div>
                        <div class="safety-label">ALT Elevation<br>(Led to pause)</div>
                    </div>
                    <div class="safety-item concern">
                        <div class="safety-value">Low Platelets</div>
                        <div class="safety-label">Thrombocytopenia<br>(0.6 mg/kg)</div>
                    </div>
                    <div class="safety-item resolved">
                        <div class="safety-value"><0.1%</div>
                        <div class="safety-label">Off-Target Edits<br>(WGS validated)</div>
                    </div>
                    <div class="safety-item resolved">
                        <div class="safety-value">Minimal</div>
                        <div class="safety-label">Germline Risk<br>(No gonadal uptake)</div>
                    </div>
                    <div class="safety-item monitoring">
                        <div class="safety-value">70%</div>
                        <div class="safety-label">Pre-existing Anti-Cas9<br>(Managed w/ steroids)</div>
                    </div>
                    <div class="safety-item monitoring">
                        <div class="safety-value">20-30%</div>
                        <div class="safety-label">Infusion Reactions<br>(Mild, transient)</div>
                    </div>
                </div>

                <div class="info-card" style="margin-top: 24px;">
                    <h3>Long-term Monitoring Requirements</h3>
                    <ul>
                        <li><strong>5-15 Year Follow-up:</strong> All patients in mandatory registry</li>
                        <li><strong>Cancer Surveillance:</strong> Annual screening for hepatocellular carcinoma</li>
                        <li><strong>Genomic Monitoring:</strong> Periodic WGS for emergent off-targets</li>
                        <li><strong>Liver Function:</strong> Quarterly LFTs year 1, then biannual</li>
                        <li><strong>Reproductive Health:</strong> Counseling on theoretical germline risks</li>
                    </ul>
                </div>

                <div class="alert alert-success" style="margin-top: 20px;">
                    <span class="alert-icon">✓</span>
                    <div class="alert-content">
                        <strong>Safety Advantages vs Other Gene Therapies:</strong>
                        No double-strand DNA breaks (unlike CRISPR), no viral vectors, liver-specific targeting, single nucleotide change only, precedent from healthy PCSK9 LOF humans.
                    </div>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Brain Safety & Low Cholesterol</h2>
                
                <div class="info-card">
                    <h3>No Cognitive Risk Expected</h3>
                    <p>PCSK9 inhibition doesn't cross blood-brain barrier. Brain cholesterol is synthesized independently from plasma LDL.</p>
                    <ul>
                        <li>Genetic PCSK9 knockouts show no cognitive deficits</li>
                        <li>Meta-analyses of PCSK9 inhibitors (LDL <20 mg/dL) show no dementia risk over 5+ years</li>
                        <li>All trials monitor neurocognition - no signals reported</li>
                        <li>EBBINGHAUS study (evolocumab) confirmed cognitive safety</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Commercial Tab -->
        <div id="commercial" class="tab-content">
            <div class="section">
                <h2 class="section-header">Pricing & Market Strategy</h2>
                
                <div class="alert alert-warning">
                    <span class="alert-icon">💰</span>
                    <div class="alert-content">
                        <strong>Expected Pricing:</strong> $1-2 million upfront, justified by lifetime benefit vs ~$100K+ in chronic drugs/events over decades. Payment models likely include annuities, outcomes-based rebates.
                    </div>
                </div>
                
                <div class="stats-grid">
                    <div class="stat-card">
                        <div class="stat-value">~1M</div>
                        <div class="stat-label">US HeFH/ASCVD Patients</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">30-50%</div>
                        <div class="stat-label">Initial Approval Rate</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">15-20 yrs</div>
                        <div class="stat-label">Break-even vs Chronic Rx</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">$2-3B</div>
                        <div class="stat-label">Peak Sales (Base Case)</div>
                    </div>
                </div>

                <div class="info-card" style="margin-top: 24px;">
                    <h3>Reimbursement Challenges</h3>
                    <ul>
                        <li><strong>High upfront cost:</strong> Budget impact concerns for payers</li>
                        <li><strong>Insurance churn:</strong> Patient may switch insurers after cure</li>
                        <li><strong>Irreversibility:</strong> Ethical and practical concerns</li>
                        <li><strong>Prior auth:</strong> Extensive documentation, step therapy failures required</li>
                        <li><strong>Coverage restrictions:</strong> Initially only severe cases with multiple therapy failures</li>
                    </ul>
                </div>

                <div class="info-card">
                    <h3>Delivery Infrastructure</h3>
                    <ul>
                        <li>Initially at specialized centers (like CAR-T model)</li>
                        <li>Medical benefit, not pharmacy</li>
                        <li>Eventually may expand to infusion centers</li>
                        <li>Requires long-term follow-up infrastructure</li>
                    </ul>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Market Scenarios</h2>
                
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Timeframe</th>
                            <th>Conservative</th>
                            <th>Base Case</th>
                            <th>Optimistic</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>2025-2027</strong></td>
                            <td>Clinical trials only</td>
                            <td>Phase 2/3 progression</td>
                            <td>Accelerated approval pathway</td>
                        </tr>
                        <tr>
                            <td><strong>2028-2030</strong></td>
                            <td>Limited HoFH approval</td>
                            <td>HeFH approval, slow uptake</td>
                            <td>Broad HeFH use, ASCVD trials</td>
                        </tr>
                        <tr>
                            <td><strong>2030-2035</strong></td>
                            <td>Niche for severe cases</td>
                            <td>Standard for genetic dyslipidemia</td>
                            <td>Primary prevention consideration</td>
                        </tr>
                        <tr>
                            <td><strong>Peak Sales</strong></td>
                            <td>$500M</td>
                            <td>$2-3B</td>
                            <td>$5B+</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- Future Outlook Tab -->
        <div id="future" class="tab-content">
            <div class="section">
                <h2 class="section-header">Critical Success Factors</h2>
                
                <div class="info-card">
                    <h3>What Must Go Right</h3>
                    <ul>
                        <li><strong>Safety Validation:</strong> No long-term adverse effects over 5+ years</li>
                        <li><strong>Efficacy Durability:</strong> Truly permanent LDL reduction demonstrated</li>
                        <li><strong>Manufacturing Scale:</strong> Consistent, scalable production achieved</li>
                        <li><strong>Regulatory Alignment:</strong> FDA/EMA satisfied with safety profile</li>
                        <li><strong>Payer Acceptance:</strong> Sustainable reimbursement models developed</li>
                        <li><strong>Public Trust:</strong> "Gene editing" fears overcome through transparency</li>
                    </ul>
                </div>

                <div class="alert alert-danger" style="margin-top: 20px;">
                    <span class="alert-icon">⚠️</span>
                    <div class="alert-content">
                        <strong>Key Risks:</strong> Unknown long-term effects, potential for delayed adverse events, regulatory delays, public/physician resistance to irreversible therapy, competition from safer/simpler approaches.
                    </div>
                </div>

                <div class="alert alert-success" style="margin-top: 20px;">
                    <span class="alert-icon">✓</span>
                    <div class="alert-content">
                        <strong>Why Lilly's Acquisition Makes Sense:</strong> Hedging across entire PCSK9 landscape, access to transformative technology, leverage existing CV infrastructure, first-mover in gene editing for common diseases, platform potential beyond PCSK9.
                    </div>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Precedents & Competition</h2>
                
                <div class="comparison-card">
                    <div class="comparison-header">
                        <div class="comparison-title">Casgevy (Vertex/CRISPR)</div>
                        <span class="badge badge-success">FDA/EMA 2023</span>
                    </div>
                    <p style="font-size: 13px; color: var(--text-secondary);">
                        First CRISPR therapy approved for sickle cell. Price: $2.2M. Ex vivo editing (not in vivo like VERVE). 
                        Shows regulatory pathway possible, high price accepted for genetic diseases.
                    </p>
                </div>

                <div class="comparison-card">
                    <div class="comparison-header">
                        <div class="comparison-title">NTLA-2001 (Intellia)</div>
                        <span class="badge badge-info">Phase 3</span>
                    </div>
                    <p style="font-size: 13px; color: var(--text-secondary);">
                        In vivo CRISPR for ATTR amyloidosis. 87% TTR reduction, no major safety issues. 
                        Most similar precedent - shows in vivo editing feasible.
                    </p>
                </div>

                <div class="comparison-card">
                    <div class="comparison-header">
                        <div class="comparison-title">Zolgensma (Novartis)</div>
                        <span class="badge badge-success">FDA/EMA 2019</span>
                    </div>
                    <p style="font-size: 13px; color: var(--text-secondary);">
                        One-time AAV gene therapy for SMA. Price: $2.1M. 
                        Payer acceptance of high-cost cures, but 20-30% abandonment rate.
                    </p>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Bottom Line Assessment</h2>
                
                <div class="info-card" style="background: linear-gradient(135deg, #E8F2FF 0%, #F8FAFB 100%); border-left-color: var(--primary); border-left-width: 4px;">
                    <h3>Strategic Outlook</h3>
                    <p style="line-height: 1.8;">
                        <strong>Near-term (2025-2027):</strong> Minimal commercial impact - still in trials<br>
                        <strong>Medium-term (2028-2030):</strong> Potential approval for severe genetic dyslipidemia<br>
                        <strong>Long-term (2030+):</strong> Could revolutionize CV prevention if safety proven<br><br>
                        <strong>Probability of Success:</strong> ~40-50% for HeFH indication by 2030<br>
                        <strong>Market Disruption:</strong> Extreme if successful, minimal if safety issues emerge<br>
                        <strong>Strategic Value:</strong> Critical optionality for future of lipid management
                    </p>
                </div>
            </div>
        </div>
    </div>

    <script>
        function showTab(tabName) {
            // Hide all tabs
            const tabs = document.querySelectorAll('.tab-content');
            tabs.forEach(tab => tab.classList.remove('active'));
            
            // Remove active from all nav tabs
            const navTabs = document.querySelectorAll('.nav-tab');
            navTabs.forEach(tab => tab.classList.remove('active'));
            
            // Show selected tab
            document.getElementById(tabName).classList.add('active');
            
            // Mark nav tab as active
            event.target.classList.add('active');
        }
        
        // Animate elements on scroll
        const observer = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    // Animate chart bars
                    const chartBars = entry.target.querySelectorAll('.chart-bar');
                    chartBars.forEach((bar, index) => {
                        const height = bar.style.height;
                        bar.style.height = '0';
                        setTimeout(() => {
                            bar.style.height = height;
                        }, index * 100);
                    });
                    
                    observer.unobserve(entry.target);
                }
            });
        }, { threshold: 0.1 });
        
        // Observe all sections
        document.querySelectorAll('.section').forEach(section => {
            observer.observe(section);
        });
    </script>
</body>
</html>